Pharma News, 2023

BioMarin’s has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA) reimbur...

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and...

The FDA has granted priority review to Roche’s biologics license application (BLA) for glofitamab for the treatment of adults with relapsed or resistant large B-cell lymphoma after two or more li...

Dutch biotech Synaffix has signed a $2 billion licensing agreement with Amgen to bring a new generation of antibody-drug conjugates (ADC) to market.

Ipsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in cash for an initial estimated aggregate consideration of $952 million plus one contingent value right ...

AstraZeneca has inked a definitive agreement to acquire cardiorenal disease player CinCor Pharma in a deal that could potentially reach $1.8 billion in total value, the companies announced Monday....

Chiesi Farmaceutici expects that the deal will expand its rare disease medicine portfolio.

Ublituximab-xiiy from TG Therapeutics Inc is the first anti-CD20 monoclonal antibody approved for individuals with RMS that is administered as a 1-hour infusion after the starting dose. ...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

The FDA has granted Breakthrough Therapy designation to Vaxcyte for its VAX-24, an investigational 24-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease, a group of bact...